Report forecasts world stem cell market.
NEW YORK, N.Y., October 13, 2014--Frost & Sullivan has published a report on the global stem cell market that provides various forecasts through 2018. Geographic regions covered in the study are North America, Europe and APAC, followed by a detailed Asia Pacific Region Analysis, which covers countries such as India, Australia, Thailand, Singapore, South Korea, Malaysia and Japan.
The stem cell market comprises three broad segments: products, technology and application.
The study covers various areas of interest such as regulatory policies within stem cell research, key business updates, analysis of risk factors, and strategic recommendations.
Key clinical milestones, timelines of key clinical events, key companies to watch, and a strategic partnership assessment in the global stem cell market have been included.
Among the key findings:
* Cord blood banking is one of the fastest growing segments of the stem cell market. The number of active cord blood banks worldwide has grown significantly from 2005 to 2013.
* APAC countries are progressing quickly in stem cell research, including human embryonic stem cells, induced pluripotent stem cell (IPSc) and others. The major hurdle has been the regulatory environment in these countries, but that has been changing lately. Several Asian countries have modified their regulations regarding stem cell research to attract more investors.
* India, Singapore and South Korea are the frontrunners in Asia and are expected to dominate the APAC stem cells market in the coming years. Favorable regulatory changes and funding support from governments have helped commercialization of the stem cell industry.
* South Korea is set to lead the stem cell research market in APAC. Funding in stem cell research in this country could be compared to that of the U.S.
* Stem cells obtained from adult organisms constitute the main focus of research; the ethics of using these cells is undisputed. Therapies employing adult stem cells are being developed by various companies (such as ViaCell, StemSource, Osiris Therapeutics, Neural Stem, and Angioblast) and are moving fast from the laboratory to the clinic.
* The majority of companies pursuing stem cell therapeutics are engaged in the development of adult stem cells derived from bone marrow, neural tissue, adipose tissue, menstrual blood, and the placenta.
To read more about the report ("Analysis Of The Global Stem Cell Market", Frost & Sullivan, 171 pages, $6,000) visit the following link.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Industry & Market Research|
|Publication:||Stem Cell Lab World|
|Date:||Oct 20, 2014|
|Previous Article:||Baker introduces cultivo CO2 incubator.|
|Next Article:||DNA sequencing market to hit $10 billion by 2017.|